Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor
Asclepius Technology Company Group (Suzhou) is developing ROBO1 CAR-NK/T cell immunotherapy targeting malignant tumors, a promising area in oncology given the increasing focus on immunotherapy. The market for CAR-T and NK cell therapies is rapidly expanding, with significant competition from established players and emerging biotech firms. Successful outcomes from this trial could position Asclepius favorably in the immunotherapy landscape, potentially leading to partnerships or acquisition interest. However, the unknown status of the trial and the competitive nature of the field necessitate thorough diligence on regulatory pathways and market access strategies.
Indication: Malignant Tumor
Modality: protein therapy
Target: ROBO1
Sponsor: Asclepius Technology Company Group (Suzhou) Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: ROBO1
View original source fields
Condition raw: Malignant Tumor
Condition normalized: Malignant Tumor
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: ROBO1
Target normalized: ROBO1